A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 26,100 shares of LGND stock, worth $2.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,100
Previous 24,400 6.97%
Holding current value
$2.96 Million
Previous $1.78 Million 23.33%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$68.53 - $87.91 $257,261 - $330,014
-3,754 Reduced 7.57%
45,810 $3.86 Million
Q1 2024

May 15, 2024

BUY
$68.64 - $89.2 $2.73 Million - $3.55 Million
39,762 Added 405.65%
49,564 $3.62 Million
Q4 2023

Feb 14, 2024

SELL
$49.57 - $72.63 $1.11 Million - $1.62 Million
-22,301 Reduced 69.47%
9,802 $700,000
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $1.72 Million - $2.12 Million
29,241 Added 1021.7%
32,103 $1.92 Million
Q2 2023

Aug 14, 2023

SELL
$69.53 - $79.33 $4.87 Million - $5.55 Million
-69,995 Reduced 96.07%
2,862 $206,000
Q1 2023

May 15, 2023

SELL
$65.67 - $77.08 $5.26 Million - $6.17 Million
-80,071 Reduced 52.36%
72,857 $5.36 Million
Q4 2022

Feb 14, 2023

BUY
$61.72 - $96.74 $8.08 Million - $12.7 Million
130,960 Added 596.14%
152,928 $10.2 Million
Q3 2022

Nov 14, 2022

BUY
$0.01 - $107.56 $219 - $2.36 Million
21,968 New
21,968 $1.89 Million
Q1 2022

May 16, 2022

SELL
$94.99 - $151.56 $129,091 - $205,970
-1,359 Reduced 42.22%
1,860 $209,000
Q4 2021

Feb 14, 2022

SELL
$127.69 - $165.85 $1.33 Million - $1.72 Million
-10,382 Reduced 76.33%
3,219 $497,000
Q3 2021

Nov 15, 2021

BUY
$102.33 - $144.73 $649,079 - $918,022
6,343 Added 87.39%
13,601 $1.89 Million
Q2 2021

Aug 16, 2021

SELL
$113.03 - $155.64 $176,665 - $243,265
-1,563 Reduced 17.72%
7,258 $952,000
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $8.88 Million - $19.2 Million
-89,190 Reduced 91.0%
8,821 $1.34 Million
Q4 2020

Feb 16, 2021

SELL
$80.55 - $106.05 $10.4 Million - $13.6 Million
-128,527 Reduced 56.74%
98,011 $9.75 Million
Q3 2020

Nov 16, 2020

BUY
$89.56 - $126.72 $12.8 Million - $18.1 Million
142,561 Added 169.76%
226,538 $21.6 Million
Q2 2020

Aug 14, 2020

SELL
$68.28 - $123.65 $7.23 Million - $13.1 Million
-105,853 Reduced 55.76%
83,977 $9.39 Million
Q1 2020

May 15, 2020

BUY
$63.37 - $107.88 $4.23 Million - $7.2 Million
66,741 Added 54.22%
189,830 $13.8 Million
Q4 2019

Feb 14, 2020

SELL
$96.94 - $113.59 $36,352 - $42,596
-375 Reduced 0.3%
123,089 $12.8 Million
Q3 2019

Nov 14, 2019

BUY
$86.25 - $120.16 $4.26 Million - $5.93 Million
49,354 Added 66.6%
123,464 $12.3 Million
Q2 2019

Aug 14, 2019

SELL
$107.38 - $129.34 $3.44 Million - $4.14 Million
-32,039 Reduced 30.18%
74,110 $8.46 Million
Q1 2019

May 15, 2019

BUY
$105.93 - $142.47 $5.24 Million - $7.05 Million
49,457 Added 87.24%
106,149 $0
Q4 2018

Feb 14, 2019

BUY
$128.36 - $272.13 $6.95 Million - $14.7 Million
54,121 Added 2105.06%
56,692 $7.69 Million
Q3 2018

Nov 13, 2018

SELL
$211.18 - $274.49 $1.89 Million - $2.46 Million
-8,949 Reduced 77.68%
2,571 $0
Q2 2018

Aug 10, 2018

BUY
$150.77 - $207.98 $1.52 Million - $2.1 Million
10,106 Added 714.71%
11,520 $0
Q1 2018

May 11, 2018

SELL
$138.63 - $182.62 $142,511 - $187,733
-1,028 Reduced 42.1%
1,414 $234,000
Q4 2017

Feb 09, 2018

SELL
$128.36 - $147.04 $172,002 - $197,033
-1,340 Reduced 35.43%
2,442 $334,000
Q3 2017

Nov 09, 2017

BUY
$120.91 - $137.94 $457,281 - $521,689
3,782
3,782 $515,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.91B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.